REZULIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rezulin, and what generic alternatives are available?
Rezulin is a drug marketed by Pfizer Pharms and is included in one NDA.
The generic ingredient in REZULIN is troglitazone. Additional details are available on the troglitazone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REZULIN?
- What are the global sales for REZULIN?
- What is Average Wholesale Price for REZULIN?
Summary for REZULIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 91 |
| Clinical Trials: | 2 |
| Patent Applications: | 3,981 |
| DailyMed Link: | REZULIN at DailyMed |
Recent Clinical Trials for REZULIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Novartis | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
| Dana-Farber Cancer Institute | Phase 2 |
US Patents and Regulatory Information for REZULIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-001 | Jan 29, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-003 | Aug 4, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-002 | Jan 29, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for REZULIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-003 | Aug 4, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-002 | Jan 29, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-002 | Jan 29, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-001 | Jan 29, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-001 | Jan 29, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-002 | Jan 29, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for REZULIN
See the table below for patents covering REZULIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hong Kong | 1011925 | ⤷ Sign Up | |
| Norway | 995932 | ⤷ Sign Up | |
| Finland | 82693 | ⤷ Sign Up | |
| China | 1106195 | ⤷ Sign Up | |
| Australia | 754479 | ⤷ Sign Up | |
| Czech Republic | 9600793 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for REZULIN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0139421 | SPC/GB97/084 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TROGLITAZONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 10949/0277 19970729; UK 10949/0278 19970729; UK 10949/0279 19970729; UK 06384/0005 19970729; UK 06384/0006 19970729; UK 06384/0007 19970729 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
